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a  b  s  t  r  a  c  t
This study  describes  experiments  carried  out  to  examine  effects  of the  antiparasitic  drug  teﬂubenzuron,
used  in  delousing  farmed  salmon,  on  a non-target  species,  the  European  lobster  (Homarus  gammarus).
Juvenile  lobsters  were  fed  two  doses  of  teﬂubenzuron,  10 and  20 mg/kg  successively  for  7  days  corre-
sponding  to a standard  medication  of  the  ﬁsh  (10  mg/kg  day)  and  twice  the standard  dose  (20  mg/kg
day).  Monitoring  lasted  3 months  to  include  at least  one  moulting  period  for all  individuals.  Cumula-
tive  mortality  was higher  in all replicates  given  medicated  feed  compared  with  the  control  group.  Mean
cumulative  mortality  for  each  dosing  was  41 ±  13%  for 10 mg/kg  and  38 ± 8% for 20 mg/kg,  i.e. no  differ-
ence.  Drug  residue  was  analysed  in  all juveniles  that  died,  in  addition  to 12  juveniles  at  day  8  and  the  ﬁrst
12  surviving  lobsters.  A decline  in  concentration  of  teﬂubenzuron  from  over  8000  ng/g  (day  5)  to  14  ng/g
(day  70)  was  observed  in  the  juveniles  that  died  during  the  experiment.  Twelve  individuals  that  died  con-
tained  82  ng/g  or  less  whereas  the mean  concentration  in  the  ﬁrst 12  lobsters  that  survived  moulting  was
152  ng/g.  Following  a  single  oral  administration,  the  half-life  of teﬂubenzuron  in  lobster  was  estimated
to  3.4  days  and  the  initial  concentration  (C0) to 515  ng/g  at  time  t0. At the  end  of  the  study  a considerable
number  of juvenile  lobsters  were  observed  with  deformities  in  various  organs;  carapace,  walking  legs,
cheliped,  tail  fan,  abdomen  and  antenna.  The occurrence  of observed  deformities  varied  from  0 to  15%
in  treated  replicates  and  will most  likely  affect  ability to locate  and  consume  food  (antenna,  claw  and
walking  legs),  respiration  (carapace)  and  ability  to move/swim  (walking  legs,  tail  fan  and  abdomen).  In
total,  the  mortality  and  senescent  damages  were  close  to 50%  in  all replicates.  Juveniles  that  survived
medication  without  deformities  however,  moulted  and increased  in size  at each  moult  equally  well as
s.
 201the  unmedicated  control
©
. Introduction
Salmon lice (Lepeophtheirus salmonis, Krøyer 1837) are small
arine ectoparasites that feed on mucous, blood and skin on
almon and trout and if present in sufﬁcient numbers, may  cause
ortality by osmotic stress and secondary infections by bacterial
nd viral pathogens. Infestation with sea lice is therefore consid-
red a major problem for the Atlantic salmon (Salmo salar) industry
n Europe and North America (Pike and Wadsworth, 1999; Costello,
006; Burka et al., 2012). In addition to reducing the general wel-
are of the farmed ﬁsh, salmon lice cause a signiﬁcant economic loss
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due to reduced growth, increased mortality, downgrading of ﬂesh
quality and the cost of delousing treatments (MacKinnon, 1997).
Excessive numbers of adult lice in a salmon farm also increase
the number of free swimming larvae in the surrounding water,
hence generating a negative impact on wild populations of sea trout
(Salmo trutta) and migrating wild post-smolts of Atlantic salmon
(Wagner et al., 2008; Costello, 2009).
Several antiparasitic agents are currently in use for delous-
ing farmed ﬁsh and the compounds are either dissolved in
water and used for bath treatment or administered orally
via the feed. In Norway, teﬂubenzuron [1-(3,5-dichloro-2,4-
diﬂuorophenyl)-3-(2,6-diﬂuorobenzoyl)urea] and diﬂubenzuron
[1-(4-chloro-phenyl)-3-(2,6-diﬂuorobenzoyl)urea]) were fre-
quently in use from late 1990s and until 2001. From 2002,
emamectin and the pyrethroids, cypermethrin and deltamethrin
Open access under CC BY-NC-ND license.were the drugs of choice but due to instances with reduced
sensitivity for these drugs, ﬂubenzurons were reintroduced in
2009. Consumption of teﬂubenzuron was 2028, 1018, 26 and
751 kg active compound in the years 2009–2012 respectively
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lubenzurons are orally administered agents that act by interfering
ith the synthesis of chitin in the salmon lice. They are effective
gainst all stages of sea lice that undergo moulting, including the
arval and pre-adult stages (Branson et al., 2000; Ritchie et al.,
002; Campbell et al., 2006a,b). Teﬂubenzuron is administered via
edicated pellets containing 2 g teﬂubenzuron per kg feed and the
ecommended dosing regimen is 10 mg/kg ﬁsh daily for 7 days. The
xcretion pathway of teﬂubenzuron in Atlantic salmon is mainly
ia the liver and bile to the intestine and the elimination is temper-
ture dependant with half-lives in muscle between 2 and 6 days
Anon, 1999). Since the bioavailability in Atlantic salmon is low
approximately 10%) and the metabolism is minimal, most of the
rug will be released from the ﬁsh as parent compound via faeces
n the period of medication and immediately following a treat-
ent (Anon, 1999). A preliminary study analysing faecal material
rom Atlantic salmon undergoing medication with teﬂubenzuron
howed concentrations more than twice the initial concentration
n the medicated feed (Samuelsen, unpublished data). Solubility
f teﬂubenzuron in water is low (0.0094 mg/L at 20 ◦C), and the
ubstance associate readily with particles rich in organic content
Marsella et al., 2000). It is therefore reasonable to believe that once
ellets and faecal material containing teﬂubenzuron reach the
arine sediment, the compound does not readily disappear. Based
n results from a Scottish study, a half-life of teﬂubenzuron of 115
ays in a marine sediment could be calculated (Langford, 2011).
t has been shown that the organic waste in the form of excess
ellets and faecal material from ﬁsh farms undergoing medication
ontains high concentrations of ﬂubenzurons (Selvik et al., 2002).
owever, concentrations found in sediment samples collected
n the vicinity of ﬁve investigated farms were much lower. The
ighest concentration was 40 mg/kg sediment (wet weight) (Selvik
t al., 2002; Langford, 2011; Samuelsen, unpublished data). In
ontrast, using a remotely operated vehicle (ROV) pellets and large
aecal particles were registered on the bottom in the vicinity of
sh farms (Kutti, 2008). It is therefore reasonable to expect that
he access to drug containing organic waste for non-target species
ill vary considerable even within a small area.
Since a major part of the teﬂubenzuron administered via ﬁsh
eed will end up in the surrounding environment, there have been
oncerns about the possible toxic effects on non-target marine biota
Burridge et al., 2010; Eisler, 1992; Fisher and Hall, 1992; Haya
t al., 2005). Since teﬂubenzuron reduces chitin synthesis, the drug
s relatively non-toxic to marine species like ﬁsh, algae and mol-
uscs, but is potentially highly toxic to any species that undergo
oulting within their life cycle, including commercially important
pecies like lobster, crabs and shrimps. A study of the effect of orally
dministered ﬂubenzurons on non-target crustacean is, however,
omplicated by the fact that the investigation must include a moult-
ng phase and the experimental set-up be designed to assure low
ortality of non-medicated control groups. Furthermore, since it is
ikely that non-target crustaceans may  ingest teﬂubenzuron from
ontaminated sediments, faeces, excess food pellets or by eating
ontaminated deposit feeders like polychaetes it is difﬁcult to pre-
ict a dosing regimen that in full represents the condition under a
sh farm. In order to have effect, a deﬁned concentration of the drug
ust probably be present in an individual at a speciﬁc time period
uring the moulting cycle. The concentration range that induces
ortality following moulting in marine non-target crustaceans
s, however, not known. Furthermore, since teﬂubenzuron affects
he formation of the new exoskeleton it is a possibility that non-
atal damage may  occur. Copepod eggs (Acartia tonsa) exposed to
iﬂubenzuron dissolved in water at 1 and 10 g/L showed reduced
atching ability and those that hatched were abnormally shaped
nd failed to moult at the next stage of development (Tester and
ostlow, 1981).xicology 149 (2014) 8–15 9
For drugs like teﬂubenzuron giving no immediate and acute
effect, knowledge of the uptake and elimination kinetics in a
speciﬁc species will provide important information in determining
the period of time after an exposure where the drug is expected to
have effect.
The aim of this study was to examine the effects of teﬂuben-
zuron on juvenile lobster when offered doses similar to the dose
administered to the farmed ﬁsh and twice this dose corresponding
to the consumption of drug containing faecal particles. Further-
more, the uptake and elimination of teﬂubenzuron in lobster was
studied following a single oral administration.
2. Materials and methods
2.1. Animals and feed
This study was  approved by the National Animal Research
Authority (NARA) in Norway and has been carried out in accordance
with The Code of Ethics of the World Medical Association for animal
experiments http://europa.eu.int/scadplus/leg/en/s23000.htm.
A series of experiments were run to assess the effects of orally
administered teﬂubenzuron on European lobster (Homarus gam-
marus). Juvenile stages of lobster were chosen as they moult more
frequently than subadults and adults. The juveniles were produced
at the Institute of Marine Research (IMR) ﬁeld station at Parisvatnet
located outside Bergen (60◦37′75′′ N, 4◦48′11′′ E) in late July/August
2010. Broodstock were collected from the surrounding area close
by, in Øygarden. Sizes of the juveniles were recorded as carapace
length (CL) measured as the distance from the posterior rim of the
eye socket to the posterior edge of carapace and total length (TL)
measured as the distance from the anterior tip of rostrum to the
end of telson. CL and TL were recorded with a calliper to the closest
0.1 mm below. Wet  body weight (BW) was  recorded on a TE2101
Sartorius scale to the nearest 0.1 g.
Two  doses of teﬂubenzuron were chosen, 10 and 20 mg/kg. The
lower dose corresponds to the dose administered to the salmon
whereas the high dose is similar to the concentration found in fae-
cal material from salmon undergoing medication. The lobsters were
fed special commercially produced pellets (3 mm)  patented by Nor-
wegian Lobster Farm (www.norwegian-lobster-farm.com/en/) and
produced by Noﬁma (www.noﬁma.no/en). The pellets had an aver-
age weight of 50 ± 5 mg.  The medicated feeds were customised
to a 3 g individual and made by homogeneously mixing 60 or
120 mg  teﬂubenzuron with 1 g glucose and using a few drops of
herring oil, and by gentle shaking the drug was coated on two
batches of 100 g pellets. Assuming even distribution, this corre-
sponds to concentrations of 30 g (low dose) or 60 g (high dose)
drug per pellet. Analysis of 10 pellets from each prepared dose
revealed an average concentration of 36 ± 6 g/pellets for low
dose and 72 ± 13 g/pellets for the high dose (analytic procedures
described in Section 2.4.1) providing doses of 12 mg/kg (low dose)
and 24 mg/kg (high dose) for a 3 g lobster.
2.2. Elimination of teﬂubenzuron
The purpose of this experiment was to assess the elimina-
tion rate of the drug from lobster and calculate the elimination
half-life. The experiment was conducted at the IMR  laboratory in
Bergen, Norway in the period 13th February to 5th Mars in 2012.
A total of 36 lobster juveniles with a mean weight of 4.3 ± 1.0 g
were used. Juveniles were kept separately in 18 cm × 16 cm × 13 cm
ﬂow-through plastic containers stacked in two stands each hous-
ing a maximum of 25 containers (5 × 5). Seawater was  obtained
from 120 m depth close to the IMR-Bergen facility, heated to a
temperature of 15.0 ± 0.5 ◦C and added to the experimental con-
tainers at a ﬂow of about 1 L/min. The juveniles were starved for
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 days prior to administration of one high-dose pellet containing
2 ± 13 g teﬂubenzuron. All 36 juveniles consumed their pellet
nd six individuals were randomly sampled at day 2, 4, 7, 11, 16
nd 20 post medication and analysed for drug residues.
.3. Simulation of a 7-day medication period–followed by
onitoring for 3 months
The main focus of this experiment was to simulate a medica-
ion period of 7 days, similar to the prescribed medication regime
t a salmon farm. The objective was to assess long-term effects
ver a 3-month period in mortality, growth and concentration of
eﬂubenzuron in lobster juveniles. The experiment was  conducted
t the IMR  ﬁeld station at Parisvatnet outside Bergen, Norway in
he period August 22 to November 23 in 2011, a total of 93 days.
he experimental period was chosen to include at least one moult-
ng for all individuals. Sea water was obtained from 25 m depth
nd the temperature in the tanks decreased during the experi-
ental period from 14 to 9 ◦C. A total of 286 lobster juveniles
ere divided into three major groups, two fed medicated pellets
high and low dose) and one control group fed un-medicated feed.
ach medicated group was divided into three replicates receiv-
ng low dose: C (n = 38), F (n = 38) and G (n = 48) and high dose:
 (n = 38), D (n = 38) and E (n = 48). Number of juveniles in the con-
rol group was 38. Replicate F in low dose and control was  run
utdoor, while the other replicates were run indoor. A net covered
he outdoor replicates. The juveniles were held separately in white
VC plastic compartments of 170 mL  (7.0 cm × 3.5 cm × 7.0 cm).
he bottom of the compartments was perforated with 2.5 mm
iameter round holes to ensure water ﬂow. Each replicate and the
ontrol consisted of 8 × 5 (or 10 × 5) compartments, termed as a
ray, held together by plastic strips. Each tray was placed in sep-
rate 600 L (1 m × 1 m × 0.6 m)  ﬂow-through ﬁbreglass tanks with
 water ﬂow of 10–15 L/min. Water level in the tanks was about
.5 m and ﬂow was set to 30–40 L/min.
Prior to the experiment, the lobsters were starved for 3 days. The
edication period lasted from day 1 to 7 and the pellet given at day
 was left for another 3 days before being removed if not consumed.
ased on previous knowledge of feed consumption, lobsters with
 weight of less than 2.0 g (n = 135 including the control) were fed
very second day (in total 4 medicated pellets) whereas lobsters
ith a weight equal to or higher than 2.0 g (n = 151 including the
ontrol) were fed daily (in total 7 medicated pellets). Each individ-
al was inspected daily during the medication period, and uneaten
ellets registered. Mortality and moulting was recorded daily. At
ay 8, the day after the last medication, two individuals from each
f the six medicated replicates were sampled and analysed for drug
esidues. Likewise, the two ﬁrst juveniles in each medicated repli-
ate that survived moulting were sampled and analysed for drug
esidues. Cumulative mortality per day was calculated subtracting
ampling at day 8 and sampling of the ﬁrst two juveniles surviv-
ng moulting in each replicate. Likewise, cumulative moulting was
alculated subtracting sampled numbers, including mortality. At
he end of the experiment (day 93), all survivors were checked for
eformities and CL, TL and BW recorded. Juveniles with deformi-
ies were monitored over several moulting periods to study the
ermanency of the damage.
.4. Analytical procedures
Teﬂubenzuron (analytical standard), diﬂubenzuron (analytical
tandard), acetonitrile, heptane, diethyl ether and acetone (all HPLC
rade) were purchased from Sigma–Aldrich (Steinheim, Germany).
etrahydrofuran (HPLC grade) and ammonium hydroxide (25%) (PA
rade) were purchased from Merck (Darmstadt, Germany). The
ater used was puriﬁed with a Milli-Q water puriﬁcation systemxicology 149 (2014) 8–15
from Millipore. Stock solutions of teﬂubenzuron and diﬂubenzuron
were prepared at a concentration of 1 mg/mL  in tetrahydrofuran
and stored at 4 ◦C. Working standards were prepared by dilution of
stock solutions with a mix  of acetonitrile:water (50:50, v/v).
2.4.1. Concentrations in feed pellets
Each pellet was  added to a 10 mL tube containing 2 mL  acetoni-
trile, shaken for 10 min  followed by transfer (1 mL)  to an Eppendorf
tube and centrifugation for 5 min  at approximately 14,500 × g using
a Biofuge A table centrifuge (Heraeus Sepatech, Osterode am Hartz,
Germany). A calibration curve for teﬂubenzuron ranging from 5
to 40 g/mL was made in triplicate by dilution of stock solution
with acetonitrile:water (50:50, v/v). Analysis of ﬁve non-medicated
pellets was  included in order to conﬁrm the absence of teﬂuben-
zuron. The samples were analysed by High-Performance Liquid
Chromatography with ultraviolet detection (HPLC-UV) using the
equipment and analytical procedure as described in Selvik et al.
(2002).
2.4.2. Concentrations in lobster juveniles
Each individual lobster was weighed, placed in a 25 mL
centrifuge tube and thoroughly crushed using a glass rod. Diﬂuben-
zuron (50 L, 0.5 g/mL) was added to the samples as internal
standard. Acetone (5–10 mL  depending on sample size) was added
and the mixture was homogenised by a whirl mixer and placed
in an ultrasonic bath (40 kHz) for 10 min  before the samples were
centrifuged for 3 min  at 2500 × g (Eppendorf Centrifuge 5810 R,
Eppendorf AG, Hamburg, Germany). The resulting extract was
transferred to a 10 mL  centrifuge tube. To remove fat, heptane
was added (1 mL)  and the solution was  shaken before centrifuga-
tion at 1250 × g for 2 min. From the resulting two-phase mixture
the upper heptane phase was  removed and discharged. This step
was repeated once. The acetone extract was evaporated to dry-
ness under nitrogen at 40 ◦C, the residue dissolved in heptane
(5 mL)  and cleaned-up by solid phase extraction using a GX-271
ASPEC (Automated Solid Phase Extraction) system from Gilson
(Middleton, USA). The solid phase extraction column, Bond Elut
Si, 500 mg,  3 mL  (Agilent Technologies, Boeblingen, Germany) was
conditioned with 2.5 mL  heptane prior to loading of the sample.
After loading, the column was  washed with 3 mL  of heptane, 5 mL
heptane/diethyl ether (95:5, v/v) and 5 mL  heptane/diethyl ether
(90:10 v/v). The analyte and internal standard were eluted with
5 mL  heptane/diethyl ether (60:40, v/v). The eluate was evaporated
to dryness using nitrogen at 40 ◦C and re-dissolved in 250 L of a
solution of acetonitrile:water (40:60 v/v). The sample was  ﬁltered
through a 0.45 m syringe ﬁlter and was  ready for analysis. For the
calibration curves, blank samples were spiked with teﬂubenzuron
at concentrations of 15–500 and 500–8000 ng/g and prepared as
described above. The standard curves were prepared in triplicate.
The samples were analysed using a HP 1100 LC-system
(Hewlett-Packard, Waldbronn, Germany) coupled to an Agilent
MSD quadrupole mass spectrometer (Agilent Technologies, Wald-
bronn, Germany). ChemStation software (Agilent Technologies,
Waldbronn, Germany) was  used for instrument control and data
analysis. The analytical column used was  a Shodex Asahipak ODP-
50 4D 4.0 mm × 125 mm,  4 m (Showa Denko, Munich, Germany).
The injection volume was  10 l. The mobile phase was  a mix-
ture of acetonitrile and aqueous ammonium hydroxide (75:25,
v/v) at an isocratic ﬂow rate of 0.7 mL/min at 25 ◦C. The retention
time was 4.8 min  for diﬂubenzuron and 5.3 min  for teﬂubenzuron.
The analyte and internal standard were analysed by negative
electrospray ionisation (ESI) and detected as their deprotonated
molecular anions by selected ion monitoring (SIM). The mass
to charge (m/z) ratio was  378.9 (qual.) and 359.0 (quant.) for
teﬂubenzuron and 309.0 (qual.) for diﬂubenzuron. The following
experimental parameters were used: nebuliser pressure, 40 psig;
atic Toxicology 149 (2014) 8–15 11
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Fig. 2. Cumulative mortality (%) in European lobster (Homarus gammarus) juvenilesO.B. Samuelsen et al. / Aqu
rying gas temperature, 350 ◦C; drying gas ﬂow, 8 L/min; needle
oltage, 3600 V; desolvating chamber temperature, 300 ◦C; frag-
entor voltage, 70 V. The limit of detection (LOD) was determined
o 5 ng/g and the method was linear (r = 0.98) over the ranges stud-
ed (15–500 ng/g, 500–8000 ng/g). Inter-run precision ranged from
.5 to 10.0%.
.5. Statistical analysis
For estimation of elimination half-life (t½ ˇ) a linear regression
nalysis was made on logarithmically (ln) transformed drug con-
entrations versus time using the formula t½ = ln 2/k, where k is
he slope of the regression line. The initial concentration (Co) was
etermined by extrapolation of the regression line to time zero (to).
nalysis of variance (ANOVA) was made on sizes comparing repli-
ates and treatments. To analyse differences between low and high
ose concentrations, analysis of covariance (ANCOVA) was applied
o log-transformed concentrations.
. Results
.1. Elimination of teﬂubenzuron
Following intake of one pellet with high dose teﬂubenzuron
72 g) the concentrations in the lobsters decreased with time
Fig. 1). The highest concentration, 602 ng/g, was measured at the
rst sampling, i.e. 2 days after intake. The lowest concentration at
hat sampling was 215 ng/g giving an indication of the individual
ariation. From the data presented in Fig. 1 an elimination halﬂife
t½ ˇ) of 3.4 days and an initial concentration (Co) 515 ng/g at time
o could be determined.
.2. Simulation of a 7-day medication period-followed by
onitoring for 3 months
.2.1. Mortality
Overall 41% (n = 46) of the juveniles administered low dose of
eﬂubenzuron died. Mortality was 30%, 39% and 56% in the differ-
nt replicates. Mortality commenced with one juvenile at day 4 and
f 15 juveniles that moulted during the medication period, 10 died
mmediately and one died when moulting for a second time at day
1 containing 15 ng/g teﬂubenzuron. The remaining ﬁve juveniles
id not moult a second time and were still alive at the end of the
xperiment. Of the juveniles exposed to a high dose of teﬂuben-
uron 38% died (n = 42) and mortality varied between 32%, 44% and
7% in the different replicates. The mortality commenced at day 5
three juveniles) and off the seven individuals that moulted dur-
ng the medication period six died. The only survivor also moulted
y = 515e-0.20 x
R² = 0.99
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ig. 1. Mean concentration of teﬂubenzuron (n = 6 at each sampling time) vs time
roﬁle in juvenile European lobster (Homarus gammarus) following a single oral
dministration of 72 g teﬂubenzuron. Standard deviation are given as vertical bars.given pellets with low or high dose of teﬂubenzuron from day 1 to 7 compared with
control with no medication in the feed. The numbers for low and high doses are the
means of three replicates.
successfully a second time at day 50 and was  alive at the end of
the experiment. For both low and high dose, more than 80% of the
mortality had taken place before day 30. In the control group total
mortality amounted to ﬁve individuals (13%), all died within the
ﬁrst 23 days. No difference was found in mean cumulative mor-
tality comparing high- and low-dose treatments at the end of the
study whereas both treatments had higher cumulative mortality
compared to the control group (Fig. 2). Some of the juveniles died
while in a moulting process as shown in Fig. 3.
Successful moulting after the last dose of medicine started at
around day 30, in both treatments. Not all moults were however
recorded as the juveniles can eat their exoskeleton in a few hours
and moultings can therefore be missed. As a consequence, only 58%
of the juveniles in the low-dose treatment were recorded to have
moulted compared to 79% in the high-dose treatment and 72% in
the control. However, in the end of the experiment, measurements
of CL and TL showed that all surviving juveniles had moulted at least
once but recordings of exact dates were missing. Four juveniles
were recorded to have moulted twice.
3.2.2. Growth
When the experiment was initiated the mean juvenile size was
16.0 ± 2.1 mm CL; 45.4 ± 6.3 mm TL and 2.2 ± 0.9 g BW and no sig-
niﬁcant difference (ANOVA, p > 0.05) were registered in CL, TL or
BW between replicates or treatment groups. In the experimental
period the lobster increased in weight and size equally in all groups
and replicates. At the end of the experiment (day 93) no signiﬁcant
difference were found in neither CL, TL or BW (Table 1) (ANOVA,
p > 0.05).3.2.3. Concentration of teﬂubenzuron in the juveniles
Due to variable appetite the prearranged dose was not con-
sumed by all individuals during the medication period. However,
as the number of pellets eaten by each juvenile was recorded it was
Fig. 3. European lobster juvenile (nr. A06) had consumed three pellets with high
dose of teﬂubenzuron before it died during the moulting process, at day 7. The new
exoskeleton is visible under the old one.
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Table 1
Summary of carapace length (CL), total length (TL) and body weight (BW) of Euro-
pean lobster (Homarus gammarus) at day 93.
Low dose High dose Control
Carapace length (mm) 18.6 ± 7.7 18.3 ± 2.3 18.0 ± 2.2
Total length (mm)  52.9 ± 5.7 52.7 ± 6.9 52.8 ± 6.5
Body weight (g) 3.7 ± 1.2 3.7 ± 1.6 3.6 ± 1.4
Number 66 68 32
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ossible to calculate the given dose for each individual. In the low-
ose group the juveniles consumed on average 79 g/g, compared
ith 173 g/g in the high-dose group. All the 12 lobsters sampled
ne day after the end of medication (day 8) consumed the appointed
umber of pellets. The mean concentrations for low and high doses
ere 1715 ± 770 and 2338 ± 1727 ng/g, respectively (Fig. 4). How-
ver, since one individual (A03) in the high-dose treatment was  a
ajor contributor to the difference, the mean value for this group
as reduced to 1666 ± 588 ng/g if A03 was excluded, giving no sig-
iﬁcant difference in mean concentration between low and high
oses. The ﬁrst six juveniles surviving low dose moulted from day
0 to 42, and those surviving high dose at day 23 (all six). The
oncentrations in these juveniles were on average 174 ± 103 ng/g
nd 130 ± 115 ng/g in low- and high-dose treatment, respectively.
here was a large variation between the juveniles, e.g. at day 23
high dose) the concentration varied from 26 to 351 ng/g.
A decline in concentration of teﬂubenzuron with time was
bserved in those juveniles that died during the experiment
Fig. 5). The highest concentrations were detected in two low-
osed juveniles with 8176 and 6843 ng/g, respectively. In the
igh-dose treatment, the highest concentration detected was
450 ng/g. Overall, there were no signiﬁcant differences in concen-
rations when comparing low and high-dosed juveniles (ANCOVA,
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Homarus gammarus) that died during the experiment. Teﬂubenzuron was  admin-
stered from day 1 to 7.Fig. 6. Ratio of % cumulative mortality and senescent damages between replicates
of  European lobster (Homarus gammarus) juveniles at day 93 when the experiment
was terminated.
p = 0.178). Mortality also occurred in individuals with low concen-
tration of the drug, and even in individuals moulting later than
60 days after medication was ended. Eleven individuals that died
contained 82 ng/g or less and the lowest concentration was  14 ng/g.
3.2.4. Deformities
When the experiment was terminated (day 93), the surviving
juveniles were inspected for deformities. Since deformities were
absent among juveniles in the control group it was assumed that
the deformities were senescent damages due to the exposure for
teﬂubenzuron. In overall, 29 of the 126 surviving juveniles were
deformed but no difference in number between low- and high-dose
treatment was found (n = 14 and 15, respectively). Deformities var-
ied between replicates from 0 to 15%, and the replicates with lowest
mortality had highest number of survivors with senescent damages
(Fig. 6). Deformities were found in the carapace, walking legs, che-
liped, tail fan, abdomen and the antennas (Table 2 and Fig. 7b–d).
Nine juveniles had developed multiple deformities and where one
juvenile had three (swollen carapace, stiff walking legs, damages to
the tail fan), while the other eight had two. The most common co-
occurring deformities were damages to the tail fan and stiff walking
legs (33%).
Affected juveniles were monitored over several moulting
periods and stiff walking legs (Fig. 7b) were replaced in one moult
whereas severe damages to the chelipeds (Fig. 7d) needed three
moultings to appear normal. Damages to the tail fan seemed per-
manent as this was  not repaired through moultings.
4. Discussion
The chitin synthesis inhibitor teﬂubenzuron is widely used as
an orally administered agent against ectoparasitic salmon lice in
marine salmon farming. Due to low bioavailability and metabolism
in the ﬁsh and high afﬁnity for organic particles a major part of the
drug will end up in the surrounding environment associated with
faeces or uneaten pellets. Concerns have been raised about possible
effects of various antiparasitic drugs used in ﬁsh farming on non-
target marine species. In this study, the effect of teﬂubenzuron was
tested on European lobster juveniles. Two  doses were used. One
represented the dose in medicated feed prescribed for the salmon,
low dose. The second, high dose, represented the higher concentra-
tion found in faeces of medicated salmon. The study showed that
lobsters were affected, either by mortality or senescent damages as
observed 3 months after medication, giving a total effect (mortal-
ity and senescent damages) of ingesting teﬂubenzuron close to 50%,
independent of whether low or high dose was  administered. The
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Table  2
Classiﬁcation of deformities found in juvenile stages of European lobster (Homarus gammarus) affected by teﬂubenzuron in the feed from day 1 to 7. Observations were made
at  day 93.
Organ affected Category Description Occurrence (%)
Carapace Puffy Carapace puffy/swollen, or up folded on one side often leaving some parts of the gills exposed 15
2nd  to 5th pereopod Stiff/twisted The joints were fused together as if over calciﬁcation made the joints grown together. The entire
pereopod leg was  like one stiff piece, sometimes “frozen” in an arbitrary/twisted position
20
1st  pereopod/cheliped Miss-shaped Various shapes of the cheliped deviating from normal 15
Uropod Damages Damages to parts of the tail fan, or even lacking one or both of the tail fans 23
Abdomen Stiff Abnormal shape of the abdomen as if some of the segments were once broken and then grown
back  in a wrong shape
18
2nd antenna Stiff Segments of the antenna were fused, almost as if over calciﬁcation made the joints grown
together. Felt “stiff” when touching. Difﬁcult to observe when animal was  out of water
10
Fig. 7. Senescent damage in juvenile European lobster (Homarus gammarus) observed at day 93 after multiple administration of the antiparasitic drug teﬂubenzuron from
day  1 to 7. (a) Normal lobster with no senescent damages, (b) damages in the walking legs, (c) swollen carapace, (d) deformed cheliped.
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ack of difference in mean cumulative mortality between high and
ow dosed groups is reﬂected in the lack of signiﬁcant difference
n mean concentrations when comparing dead juveniles from each
ose and in the concentrations measured in 12 individuals after last
edication.
Simulating a 7-day medication period does not necessarily
imic  the natural conditions under a ﬁsh farm since lobsters in the
ild have the possibility to choose from a variety of food sources.
owever, no preferences were found in a study giving European
obster juveniles the option to choose between medicated pel-
ets (teﬂubenzuron), non-medicated pellets or Artemia sp. (Jelmert,
npublished data). In our study only drug-containing pellets were
ffered to the lobsters, and the dosing regimen could be regarded as
 worst-case scenario. On the other hand, in controlled experiments
t was shown that juveniles are able to collect and store food in e.g.
ubstrate and/or shelter. If this is the case in the wild, the num-
er of stored and consumed medicated pellets may  even exceed
hat was administrated in this experiment. However, as one of the
ims of the study was to gain information concerning which con-
entrations of teﬂubenzuron induced mortality in juvenile lobster,
e found the experimental set-up legitimate to use.
Elimination halﬂife (t½ ˇ) of teﬂubenzuron after a single dose
dministration of 72 g was 3.4 days at a temperature of 15 ◦C.
o elimination data are available for teﬂubenzuron in crustaceans
ut in Atlantic salmon muscle, t½  ˇ values of 4.7 and 2.6 days,
espectively, were found following a single oral administration of
0 mg/kg of teﬂubenzuron or multiple administrations of 10 mg/kg
aily for 7 days (Anon, 1999). The salmon were held at 10 ◦C. At 6 ◦C
he t½  ˇ value following a multiple-dose study was 3.8 days (Anon,
999). The elimination in lobster juveniles was therefore found to
e in the same range as in Atlantic salmon muscle. However, as the
rug could be detected 60 days (approximately 18 half-lives) after
edication in lobster, it is possible that teﬂubenzuron is distributed
ccording to a two-compartment model and that, due to the exper-
mental period of only 20 days, a second and slower elimination
athway was not revealed.
When comparing results from the single and multiple adminis-
rations in this study it is clear that multiple administrations caused
 build up of the drug in the lobster body. However, the differ-
nce in mean concentrations after 8 days comparing low- with
igh-dose treatment was non-signiﬁcant which may  indicate lower
alatability administering the high dose pellets and/or decreased
bsorption rate with increasing dose, processes that previously has
een described for antibacterial agents in ﬁsh (Hustvedt et al., 1991;
igos et al., 1999). Furthermore, lobsters this size will break up
he pellet in smaller pieces while eating and the amount of spill
s difﬁcult to measure, which may  account for the large individual
ariations in concentrations that was observed.
There are very few data available describing the mortal effect of
ubenzurons, particularly on non-target marine crustaceans and
fter oral administration of the drug. While LC50 values have been
stablished for a number of terrestrial insects and also some aquatic
rustaceans when exposed to the drugs dissolved in water (summ-
rised in Langford, 2011), studies involving the effect of orally
dministered drugs are sparse. Scottish Environmental Protection
gency (SEPA) have considered the ecotoxicity of teﬂubenzuron
hen used as an anti sea-lice agent in aquaculture and set an
nvironmental Quality Standard (EQS) value for teﬂubenzuron in
arine sediment to 2 ng/g (dry weight). The deﬁned EQS value was
ased on a No Observable Effect Concentration (NOEC) value for the
mphipod Corophium volutator after a chronic exposure for 28 days
nd a safety margin of 10 (SEPA, 1999). Unfortunately no detailed
nformation was given about the experimental set-up and ﬁndings,
xcluding a direct comparison of results.
This study showed that individuals survived moulting 3 weeks
fter the last medication and with a concentration of 350 ng/gxicology 149 (2014) 8–15
teﬂubenzuron. In contrast, 11 individuals died with concentra-
tions of 82 ng/g or less, the lowest 14 ng/g. This demonstrates the
variation in sensitivity between individuals and made it difﬁcult
to determine a break point, where higher concentrations most
likely would induce mortality and lower concentrations most likely
would not. On the other hand, the study reveals the lower con-
centration range that induces mortality in lobster juvenile and
consequently indicates the concentration range that might have
effect on other non-target crustaceans, providing similar sensi-
tivity. In two ﬁeld studies the concentrations of teﬂubenzuron
were measured in crustaceans trapped in the vicinity of ﬁsh farms
during and shortly after medication (Langford, 2011; Samuelsen,
unpublished results). Langford (2011) found minor residues of the
drug (between 0.2 and 11.3 ng/g) in deepwater prawns (Pandalus
borealis) collected by trawl 1–5 km away from the farms and a
maximum of 185.7 ng/g in brown crab (Cancer pagurus) caught by
traps at a distance of 100–300 m from the farms. In the study by
Samuelsen (unpublished results) crustaceans were trapped within
an area of 300 m from a commercial farm under treatment and
drug residues were found in all examined species. The maximum
concentrations were 200 ng/g in deepwater prawns, 319 ng/g in
Norway lobster (Nephrops norvegicus), 393 ng/g in squat lobster
(Munida sp.) and 865 ng/g in King crab (Lithodes maja) indicat-
ing that the concentrations of teﬂubenzuron in deﬁned individuals
were high enough to induce mortality if moulting was  impending.
Lobster is covered by an exoskeleton that needs to be shed in
order to grow. Since teﬂubenzuron reduces chitin synthesis, it is
assumed that mortality in all the medicated individuals was con-
nected with ecdysis. The exoskeleton is divided into three layers all
consisting of chitin, protein, calcium and magnesium salts, phos-
phates and a few other components, but where the composition
varies in the different layers (Bobelmann et al., 2007; Romano et al.,
2007; Al-Sawalmih et al., 2008; Sachs et al., 2008; Fabritius et al.,
2009; Kunkel et al., 2012). Moulting in lobster is a complex process
and it might be that chitin is formed during a short period during the
moulting process, and vulnerability is higher during this stage. The
working mechanism of ﬂubenzurons in blocking the chitin synthe-
sis will affect formation of the new exoskeleton leading to a thinner
and weaker structure. The cause of death may  be disruption of
blood vessels in the process of liberation from the old exoskeleton.
No examination of the thickness and stratiﬁcation of the exoskele-
ton were, however, performed in this study but an ongoing study
aims at recording the changes that take place in the exoskeleton
in lobster juveniles during a moulting period, and revealing how
teﬂubenzuron is affecting the process.
This study is the ﬁrst to report a considerable number of juve-
nile lobsters with different abnormalities following administration
of teﬂubenzuron. Nevertheless a similar effect was  reported already
in 1981 on the copepod, A. tonsa by Tester and Costlow (1981) who
found that the hatching viability was less than 50% after a 12-h
exposure to 1 g/L of diﬂubenzuron and less than 5% after 24-h
exposure to 10 g/L. Those that hatch were abnormally shaped and
failed to moult at the next stage of development. In contrast, juve-
nile lobsters with abnormalities in our study were able to moult
successfully and start regenerating the damaged parts. However,
since the deformities most likely will affect the ability to locate
and consume food (antenna, claw and walking legs), respiration
(carapace) and ability to move/swim (walking legs, tail fan and
abdomen) the possibility that they will survive in the wild is small.
Interestingly, our study revealed no negative effect on growth of
juveniles that survived medication without deformities, compared
with controls.It has been shown that ﬂubenzurons are present in the sediment
and sediment dwelling organisms for an extended time after med-
ication of a farm (Langford, 2011; Selvik et al., 2002, Samuelsen,
unpublished results). Further research should therefore include
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ong-term exposure of juvenile lobsters to lower drug concentra-
ions and furthermore to include other important crustacean like
rabs, shrimps and crayﬁsh. Such data are deemed necessary in
rder to evaluate the environmental effects of ﬂubenzurons when
sed in aquaculture.
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